Skip to main content
MedPathMedPath Home
Clinical Trials/RBR-1047fwbf
RBR-1047fwbf
Active, Not Recruiting
Phase 1

Pilot study to verify the safety and efficacy of Doxycycline in the treatment of levodopa-induced dyskinesias in patients with Parkinson's disease

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 sitesMay 12, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Status
Active, Not Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2022
End Date
May 30, 2022
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Eligibility Criteria

Inclusion Criteria

  • •Patients 18 years of age or older; diagnosed with Parkinson's disease according to the United Kingdon Parkinson's Disease Society Brain Bank clinical diagnostic criteria; presenting at the initial evaluation with at least some functional impact dyskinesias (score higer than1 on item 4\. 2 of the Movement Disorder Society \- Unified Parkinson's Disease Rating Scale (MDS\-UPDRS); who are using levodopa at least three times a day; and who can keep doses of antiparkinsonian medications unchanged for at least four weeks prior to screening and during study participation.

Exclusion Criteria

  • •Diagnosis of atypical or secondary parkinsonism; treatment of any experimental drug or other intervention within 90 days prior to screening or baseline assessment; presence of moderate or severe psychotic symptoms (score greater than 2 on item 1\. 2 of the Movement Disorders Society's Unified Scale for Assessment of Parkinson\`s disease; diagnosis of dementia according to the Movement Disorders Society diagnostic criteria; suffering from serious systemic conditions (infections, malignancies, chronic kidney or liver disease); pregnancy or lactation; history of hypersensitivity or allergic reaction to tetracyclines; absence of clinical dyskinetic movements at baseline assessment.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Pilot cml autograft/glivec (STI571)/Intron A trialAdvanced phase chronic myeloid leukaemiaPh-positive acute lymphoblastic leukemiaCancer - Leukaemia - Acute leukaemia
ACTRN12605000071628Australasian Leukaemia and Lymphoma Group48
Unknown
Phase 2
Phase 2 study of DS-8500aType 2 Diabetes Mellitus
JPRN-jRCT2080222546DAIICHISANKYO Co.,Ltd.90
Completed
N/A
Combination therapy of Visudyne, Minocycline, Dexamethasone and Ranibizumab (VIMDER) for the treatment of subfoveal choroidal neovascularisation (CNV)
ISRCTN34410935King's College Hospital NHS Foundation Trust (UK)20
Completed
N/A
A pilot study to examine the safety and efficacy of posterior juxta-scleral (80 mg) triamcinolone acetonide, administration, in addition to Visudyne (verteporfin) photodynamic therapy for predominantly classic choroidal neovascularisation secondary to age-related macular degeneration: an open-label, randomised, active controlled trial
ISRCTN33957677King's College Hospital (UK)80
Completed
N/A
To determine the safety and effectiveness of Dandruff ControlOil Shots in dandruff reduction in Healthy Adult HumanSubjects with Dandruff on the scalp
CTRI/2022/04/041701Brillare Science Private Limited16